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tion, where MPR may overstate true adherence. DPR should be
considered when a measure of adherence to a class of medica-
tions is sought, particularly in clinical situations where multiple
medications within a class are often used concurrently.
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OBJECTIVE: The proportion of patients with schizophrenia
considered as being non-compliant with antipsychotic medica-
tions ranges from 20% to 89%. Non-compliance has been asso-
ciated with increase relapse rates, more frequent and longer
hospitalizations. Costs of schizophrenia in the U.S. vary from
$32 to $65 billion, but contradictory results have been reported
for the costs of non-compliance among these patients. The
objective was to estimate the costs of non-compliance with anti-
psychotic medications among patients with schizophrenia.
METHODS: A literature review of studies published in the
last decade was conducted. We utilized PubMed, Cochrane,
EMBASE and CINADHL databases. The key terms included:
(ﬁrst: adherence, non-adherence, compliance, non-compliance),
AND (second: schizophrenia, antipsychotics, atypical and typical
antipsychotics, neuroleptics) AND (third: resource utilization,
resource use, costs, economics, hospitalizations). Studies with
data on costs of non-compliance or compliance were included.
Two independent researchers reviewed the titles and abstracts
and any differences were agreed by consensus. Costs were trans-
formed in 2007 US dollars using the medical care price index.
RESULTS: Of 43 studies, six fulﬁlled the inclusion criteria,
including ﬁve retrospective cohort studies that used Medicaid
paid claims, and a cross-sectional study that used the UK Psychi-
atric Morbidity Survey. Most studies had <3 years of follow-up.
A total of 52,512 participants were studied. The percentage of
non-compliant patients ranged from 11% to 31%. A study found
that users of atypical antipsychotics (72%) have higher compli-
ance than users of typical antipsychotics (56%). Non-compliant
patients spent, on average, ten more days in the hospital, and
have 22% more rehospitalizations than compliant patients.
Costs of care for non-compliant patients were on average $3,104
higher than for compliant patients. CONCLUSION: Patients
non-compliant with antipsychotics had more and longer hos-
pitalizations, and higher total costs than compliant patients.
Non-compliance with antipsychotics has signiﬁcant clinical and
economic implications for patients with schizophrenia.
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OBJECTIVE: To compare time to all-cause discontinuation
(TTAD) across alternative antipsychotics in the treatment of
bipolar disorder (BD). METHODS: Data from a commercial
health plan from July 1, 2003 to June 30, 2006 were used to
identify non-institutionalized patients with bipolar disorder
(ICD-9 296.4–296.8) but no history of schizophrenia (ICD-9
295.xx). Patients initiating treatment using a typical antipsy-
chotic (TAP), atypical antipsychotic (AAP: aripiprazole, olanza-
pine, quetiapine, risperidone or ziprasidone), mood stabilizer or
antidepressant were included. Episodes were divided into three
categories: restarting treatment after a break in drug therapy >15
days with the drug used in the previous episode, switching
therapy with or without a break in treatment, and augmentation
therapy. First observed episodes were excluded from the analysis
due to uncertainty concerning the patient’s prior treatment
history. A total of 106,447 episodes were included in the analyses
using ordinary least squares (OLS) regression models of TTAD
adjusting for age, gender, geographic region, drug use history,
prior medical care use, bipolar disorder diagnosis and co-morbid
medical conditions. RESULTS: Augmentation constituted over
half of all treatment episodes (55.3%) and only 20% of all
episodes included an antipsychotic. Patients initiating augmenta-
tion episodes achieved signiﬁcantly longer TTAD initial therapy
than patients initiating restart (+80 days, p < 0.0001) or switch-
ing episodes (+13 days, p < 0.0001). Moreover, these estimated
differences increased signiﬁcantly when TTAD was measured
over all BD-related therapies (+155 days and +284 respectively).
OLS results comparing initial therapies favored quetiapine,
ziprasidone and aripiprazole relative to TAP in restart (+15 to
+36 days), switching (+18 to +25 days) and augmentation epi-
sodes (+28 to +48 days)(p < 0.05 for 7 of 9 estimates). CON-
CLUSION: In a commercially-insured population, patients with
bipolar disorders initiating therapy using ziprasidone, aripipra-
zole or quetiapine have longer TTAD that TAP patients. Patients
initiating augmentation therapy have much longer TTAD than
other patients, especially when measured across all psychotropic
medications.
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OBJECTIVE: To compare time to all-cause discontinuation
(TTAD) across alternative antipsychotics in the treatment of
schizophrenia. METHODS: Data from a commercial health
plan from July 1, 2003 to June 30, 2006 were used to identify
non-institutionalized patients with schizophrenia (ICD-9 codes
295.xx) who initiated treatment using a typical antipsychotic
(TAP), atypical antipsychotic (AAP: aripiprazole, olanzapine,
quetiapine, risperidone or ziprasidone), mood stabilizer or anti-
depressant. Episodes were divided into three categories: restart-
ing treatment after a break in drug therapy >15 days with the
drug used in the previous episode, switching therapy with or
without a break in treatment, and augmentation therapy. First
observed episodes were excluded from the analysis due to uncer-
tainty concerning the patient’s prior treatment history. A total of
21,872 episodes were included in the analyses using ordinary
least squares (OLS) regression models of TTAD adjusting for age,
gender, geographic region, drug use history, prior medical care
use, schizophrenia diagnosis and co-morbid medical conditions.
RESULTS: Only 39.3% of all episodes involved an antipsychotic.
Antipsychotics were used predominately as augmentation
therapy (55%) with the remaining episodes of antipsychotic drug
therapy evenly divided between restart (23%) and switching
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(22%) episodes. Unadjusted mean TTAD in days on initial
therapy measured across all episode types was 172 for TAP and
risperidone; 177 for olanzapine; 180 for antidepressants; 196 for
mood stabilizers; 202 for quetiapine; 206 for aripiprazole; and
213 for ziprasidone. We estimated that TTAD on initial therapy
was shorter for AAP patients restarting therapy relative to TAP
patients (range +2 to -33 days), but generally longer for AAP
patients switching therapies (range -14 to +27 days). Three AAPs
displayed signiﬁcantly longer TTAD in augmentation: +23 days
for quetiapine (p < 0.05); +43 days for aripiprazole (p < 0.0001)
and +56 days for ziprasidone (p < 0.0001). CONCLUSION:
In a commercially-insured population, AAPs are associated with
longer TTAD than TAPs in augmentation therapy.
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OBJECTIVE: Medication complication is one of the important
determinants in schizophrenia treatment outcomes, as it has been
found that approximately two thirds of those with schizophrenia
are readmitted to hospitals due to partial or non- compliance.
This study aimed to investigate medication compliance in those
with schizophrenia, and examine factors associated with their
compliance. METHODS: Subjects who had ever received any
outpatient antipsychotic therapy (amisulpride, risperidone, olan-
zapine, quetiapine, ziprasidone, haloperidol, or sulpiride) from
the Yuli Veterans Hospital, Taiwan, during August and Novem-
ber 2006 were identiﬁed from medical chart review. The selected
subjects were surveyed on information such as their medication
compliance, sociodemographics, treatment-related side effects,
perceived social support, and perceived treatment-related ben-
eﬁts. Their physicians were surveyed for their medication
compliance, and clinical characteristics such as CGI and comor-
bidities. Chi-square test and logistic regression model were
adopted to evaluate associations of characteristics with the medi-
cation compliance. RESULTS: Of the 81 subjects surveyed, 41
(51%) had 100% self-reported medication compliance con-
ﬁrmed by their physicians. The average age was 41, and 64% of
the sample was male. Age, education level, and work were sig-
niﬁcantly associated with different medication compliance. The
regression result showed that more than nine years of education
and work were signiﬁcantly associated with an increased likeli-
hood of 100% medication compliance. CONCLUSION: Accord-
ing to our preliminary ﬁndings, higher education level and work
were associated with 100% medication compliance. This study
selected those who had ever received certain ﬁrst-generation and
second-generation antipsychotics. However, second-generation
antipsychotics were not found to be associated with 100% medi-
cation compliance.
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OBJECTIVE: To examine the impact of duloxetine, venlafaxine
and escitalopram use and associated copays on medication per-
sistence, HEDIS standards for depression, medical utilization and
health care costs. METHODS: Medical and pharmacy claims
data were used to develop a sample of adult users with: a)
minimum two claims for duloxetine, escitalopram or venlafaxine
XR; b) maximum 120 days between the index (initial)and last
claim for a target drug; and c) minimum of 6 months enrollment
following the index claim. Propensity analysis was used to match
individuals in each drug group based on age, gender, risk
adjuster, and disease severity. Multiple regression was used to
examine the impact of anti-depressant use and prescription
copays on the change in days supply (persistence), likelihood of
meeting HEDIS standards, total pharmacy and medical expendi-
tures, and medical utilization. RESULTS: Over a 6-month
period, a $10 increase in prescription copay resulted in a one day
decrease in persistence for duloxetine users and a half day
increase in persistence for venlafaxine users compared to escit-
alopram users. Increase in prescription copay was associated
with greater likelihood of meeting HEDIS standards for all drug
therapy groups. Venlafaxine users were 1.06 times more likely to
meet HEDIS standards than escitalopram users. A $10 increase
in prescription copay increased pharmacy costs by $12 per
member for duloxetine users and $15 per member for venlafax-
ine users compared to escitalopram users. A $10 increase in
prescription copay decreased total health care costs by $4.30 per
member. Increased prescription copay resulted in non-signiﬁcant
reductions in the utilization of inpatient admissions, ER and
outpatient visits. CONCLUSION: Higher prescription copays
reduced persistence and pharmacy expenditures for antidepres-
sant users. Smaller decreases in health care expenditures were
also seen. Health plan decision makers should consider the
impact of prescription copays on patient behavior and all com-
ponents of health care expenditures.
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OBJECTIVE: We examined the relationship between self-
reported health status data, subsequent cholinesterase inhibitor
medication adherence and health care service use in older adults
with dementia in a managed care setting. METHODS: This was
a longitudinal cohort study of older adults in the southeastern
USA with dementia who completed a health status assessment,
used cholinesterase medications and were enrolled in an HMO
continuously for one year after start of cholinesterase medica-
tions for dementia. Demographic, clinical and use related eco-
nomic variables were also retrieved from the administrative
claims data of patient HMOs. Prescription reﬁlls were used to
measure medication persistence using a proportional hazards
model. Associations were examined with a sequential, mixed
model regression approach. RESULTS: A total of 116 patients
were included. The overall persistence rate in this population was
58.7% and 81% of the study population had a persistence rate of
80% or higher. After controlling for other confounding variables,
persistence (of 80% and higher) to cholinesterase therapy
remained the strongest predictor of decreased total annual health
care costs (p < 0.05). Other factors independently associated
with increased costs included increased comorbidity severity,
poor general health status, and increased number of prescription
medications (all p < 0.05). CONCLUSION: We found strong
associations between decreased cholinesterase medication persis-
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